JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data

Published 28/07/2025, 13:18
JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data

Investing.com - JPMorgan maintained its Overweight rating and $35.00 price target on Upstream Bio (NASDAQ:UPB) as the company approaches multiple clinical readouts. The stock, currently trading at $13.63, has shown strong momentum with a 28% gain in the past week. According to InvestingPro data, analyst targets range from $35 to $75, suggesting significant upside potential.

The investment bank expects Upstream Bio to deliver positive Phase 2 results with its lead asset, verekitug, across multiple type 2 inflammatory conditions over the next nine months.

Data from the chronic rhinosinusitis with nasal polyps (CRSwNP) trial is expected this quarter, followed by severe asthma results in the first quarter of 2026.

JPMorgan noted that the severe asthma data should be "more inflective in nature," suggesting these results could have greater impact on the company’s outlook.

The firm highlighted that Upstream Bio has sufficient cash to fund operations through 2027, providing runway beyond these upcoming clinical milestones.

In other recent news, Upstream Bio has initiated a Phase 2 clinical trial for its drug candidate verekitug, aimed at treating chronic obstructive pulmonary disease (COPD). The VENTURE trial will evaluate the efficacy and safety of verekitug in approximately 670 adults with moderate-to-severe COPD, with participants receiving various doses over treatment periods ranging from 60 to 108 weeks. Additionally, Upstream Bio has appointed Stacy Price as the new Chief Technology Officer. Price brings over 25 years of experience in the biotech industry and will focus on expanding technical operations and product development, particularly for verekitug. Her previous roles include Chief Technology and Manufacturing Officer at Invivyd and Chief Technical Officer at Akouos. Price’s educational background includes degrees in Biochemical and Chemical Engineering from Tufts University. These developments highlight Upstream Bio’s ongoing efforts in advancing its drug pipeline and strengthening its leadership team.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.